シャーガス病(アメリカトリパノソーマ症)治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0518
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:90
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Chagas Disease (American Trypanosomiasis) – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease (American Trypanosomiasis) – Pipeline Review, H2 2019, provides an overview of the Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline landscape.

Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Chagas Disease (American Trypanosomiasis) – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chagas Disease (American Trypanosomiasis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 5 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 18 and 5 molecules, respectively.

Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (American Trypanosomiasis) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Chagas Disease (American Trypanosomiasis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chagas Disease (American Trypanosomiasis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chagas Disease (American Trypanosomiasis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (American Trypanosomiasis) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chagas Disease (American Trypanosomiasis) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chagas Disease (American Trypanosomiasis) – Overview
Chagas Disease (American Trypanosomiasis) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chagas Disease (American Trypanosomiasis) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chagas Disease (American Trypanosomiasis) – Companies Involved in Therapeutics Development
AstraZeneca Plc
Bayer AG
Cesa Alliance SA
Collaborations Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Diakonos Research Ltd
Eisai Co Ltd
Evotec SE
GlaxoSmithKline Plc
Grupo Praxis Pharmaceutical SA
Novartis AG
Oblita Therapeutics BVBA
Sanofi
Synstar Japan Co Ltd
Chagas Disease (American Trypanosomiasis) – Drug Profiles
Chagas Disease (American Trypanosomiasis) – Dormant Projects
Chagas Disease (American Trypanosomiasis) – Discontinued Products
Chagas Disease (American Trypanosomiasis) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by AstraZeneca Plc, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by Bayer AG, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by Cesa Alliance SA, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by Collaborations Pharmaceuticals Inc, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by Diakonos Research Ltd, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co Ltd, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by Evotec SE, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by GlaxoSmithKline Plc, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by Novartis AG, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by Oblita Therapeutics BVBA, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H2 2019
Chagas Disease (American Trypanosomiasis) - Pipeline by Synstar Japan Co Ltd, H2 2019
Chagas Disease (American Trypanosomiasis) - Dormant Projects, H2 2019
Chagas Disease (American Trypanosomiasis) - Discontinued Products, H2 2019

【掲載企業】

AstraZeneca Plc
Bayer AG
Cesa Alliance SA
Collaborations Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Diakonos Research Ltd
Eisai Co Ltd
Evotec SE
GlaxoSmithKline Plc
Grupo Praxis Pharmaceutical SA
Novartis AG
Oblita Therapeutics BVBA
Sanofi
Synstar Japan Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[シャーガス病(アメリカトリパノソーマ症)治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆